Christopher Cole

Dave Miller, PhD, explains how environmental audits, waste reduction, and supply chain security are reshaping priorities in pharmaceutical manufacturing.

Sustainability Becomes Essential: Green Manufacturing and Supply Chain Resilience in Bio/Pharma



In part 4 of our 5-part interview series on the current CDMO landscape, Dave Miller, PhD, chief scientific officer at AustinPx, discusses the growing centrality of sustainability in pharmaceutical manufacturing, noting how it has shifted from a peripheral concern to a core industry requirement. He observes that over the past five years, eliminating harmful solvents, reducing carbon footprints, and strengthening supply chain resilience have moved from “nice-to-have” benefits to mandatory criteria for many large pharmaceutical companies. “The conversation on sustainability… has changed dramatically,” Miller says, pointing to evolving client expectations and more rigorous environmental audits.

He explains that sustainability now factors into multiple aspects of drug product development, from the choice of manufacturing processes to the selection of raw materials and excipients with lower environmental impact. Clients increasingly examine how CDMOs handle waste streams, ensure responsible disposal of pharmaceutical byproducts, and minimize reliance on energy-intensive inputs. Miller notes that these environmental measures are not just regulatory or ethical requirements but also a competitive differentiator, especially for domestic CDMOs whose practices are transparent and verifiable compared with some overseas operations.

The shift toward sustainability is also linked to supply chain security. By reducing dependency on certain inputs and adopting greener, more efficient manufacturing processes, companies can mitigate risk while meeting environmental goals. For Miller, this convergence of operational resilience and environmental responsibility marks a significant transformation in the way the industry defines quality and long-term value.

Check out previous parts of the interview series with Miller:

Part 1 - Collaborative Innovation in CDMOs: Dave Miller, PhD, on Early Engagement, IP Strategy, and Advanced Formulation

Part 2 - The Importance for CDMOs of Partnering With a Sponsor’s Mindset

Part 3 - Onshoring’s Unexpected Benefits: Quality, Efficiency, and Supply Chain Resilience

And be on the lookout for part 5 to drop on Monday, August 18!

Dr. Miller brings over two decades of pharmaceutical development experience and has spent his career investigating ways to improve the bioavailability of poorly soluble molecules. As CSO of AustinPx, Dr. Miller leads the pharmaceutics and analytical development teams and oversees the application of the KinetiSol Technology. Prior to his current position, Dr. Miller served as Vice President of Research and Development at DisperSol Technologies and Senior Principal Scientist at Hoffmann-La Roche. Dr. Miller specializes in formulation and processing technologies for improving oral bioavailability of insoluble small molecules. He has applied his expertise toward advancing numerous drug candidates through all stages of development from early discovery to line extension. Dr. Miller is a co-inventor of the pharmaceutical applications of the KinetiSol technology and continues to be a key innovative driver for application and expansion of the platform. He has published over 40 research articles in peer-reviewed journals, authored 8 book chapters, and is co-editor of the First, Second, and Third Editions of the textbook, Formulating Poorly Water-Soluble Drugs. He is a co-inventor on numerous granted and pending patents worldwide. Dr. Miller holds a BS in Chemical Engineering and a PhD in Pharmaceutics from the University of Texas at Austin.

*Editor’s Note: This transcript is a direct, unedited rendering of the original audio/video content. It may contain errors, informal language, or omissions as spoken in the original recording.

Yeah, that's a good question, and it's taken on some different nuances for us. What's near and dear is our KinetiSol technology. Its origins are in the plastics recycling space. So, as the history of the technology, I was a graduate student at the University of Texas, my co-inventor, Chris Brough, was an industrial engineer, developing a novel plastics recycling technology. He'd actually already developed it and was commercializing it at the point when I met him and recognized the value in that technology for creating novel pharmaceutical compositions, but also in doing so as a side effect, it was like, if we could utilize this platform, as opposed to traditional platforms like spray drying in pharmaceutics, we could eliminate a lot of solvent waste. So, the origins of the technology were already in recycling and trying to conduct manufacturing and improve in a more environmentally friendly way, to improve the environment.

It was sort of a green approach when we started back in 2007, but when we brought it over into the pharmaceutical industry, and one of the key advantages aside from the compositions we could create was we're eliminating solvents… this is gonna be great. All these chlorinated solvents that are being used to create these formulations, all these toxic solvents, the energy that goes into evaporating and recovering solvents, we're eliminating all of that.

And we thought that back in 2007, up until for several years thereafter, we thought that was a disadvantage. But when we would talk to large pharma partners, it's a nice to have, right? It's ultimately, we need the product, but if in turn you can also eliminate solvents and it's more environmentally friendly, that's a small cherry on top.

But that conversation has changed dramatically in the last five years, where eliminating solvents and being more environmentally friendly and reducing carbon footprint and shoring up the supply chain by eliminating some, some key inputs to the manufacturing process that you no longer need to consider, that's become extremely important now.

So, the conversation’s changed. From when we started to where we are now, that sustainability requirement has not just a check checkbox; now, it's mandatory. A lot of our large pharma clients that have historically used organic solvents in their drug product manufacturing, particularly to enable molecules, are now actively pursuing greener options.

And we just find ourselves in the right place at the right time. So, starting with our KinetiSol technology, we are seeing sustainability as being key. And, also, our clients audit us to ensure that we're good global citizens and that we handle our waste streams appropriately. We have all the environmental measures in place to ensure that, you know, we're not dumping pharmaceutical waste into bodies of water nearby, and I think that's another differentiator in the CDMO space for domestic versus, say, Eastern markets. You're never really exactly sure, what their sustainability practices are, but for us, it's part of the audit process now is seeing how we handle our waste streams. So, yeah, the conversation on sustainability with respect to environmental friendliness has changed dramatically.

And I think we were always there at the start. Our focus was to move a green technology to the forefront. And then sustainability has also sort of shifted into, as I touched on before, shoring up the supply chain, making sure that the inputs to your manufacturing process are also green, sustainable, and again, with processes like our KinetiSol, you can eliminate things like organic solvents, the need for purified nitrogen, , utilizing excipients that don't require the same sort of energy consumption and the carbon footprint to create. I think it's really important. Like I said, we've seen a sea change in sentiment with respect to green technology from when we started to today, and it's becoming an area where we are ahead of the competition in terms of winning new business. When they look at our approach to green manufacturing and recognize we've been here all along, ringing that bell, and it's more than just a cherry on top now. It's essential. It's a foundation.

Videos

Dave Miller, PhD, discusses how shifting drug manufacturing to domestic CDMOs can improve quality, reduce rework, and enhance long-term efficiency.

Onshoring’s Unexpected Benefits: Quality, Efficiency, and Supply Chain Resilience

In part 3 of our 5-part interview series on the current CDMO landscape, Dave Miller, PhD, chief scientific officer at AustinPx, addresses the growing trend of onshoring and nearshoring in pharmaceutical development and manufacturing, noting its roots in the current geopolitical climate. He views the shift as both a proactive strategy and a necessary contingency to respond to global uncertainty. “I think it’s a good strategy… either as a primary approach for developing and manufacturing drug products, as well as, the whole supply chain flowing into that drug product,” Miller said.

While many companies have been outsourcing to Eastern markets for speed and cost advantages, Miller notes that some AustinPx clients who have returned operations to the United States are finding unexpected benefits that include reduced miscommunication, fewer data inconsistencies, and avoidance of repeated work. Although domestic operations may initially appear slower and more expensive, the overall process can save time and resources by eliminating inefficiencies and improving quality control, he adds.

Miller observes that what began as a reaction to tariffs and geopolitical instability has evolved into a broader recognition of the value offered by high-quality domestic CDMOs. The trend highlights a shifting emphasis from cost and speed alone to prioritizing quality, reliability, and regulatory confidence—factors that can ultimately shorten timelines and improve outcomes when “doing it right the first time.”

And be on the lookout for parts 3-5 to drop in the coming days!

I think we are. We're seeing the effects of onshoring manufacturing. The geopolitical environment right now is uncertain. I think that it's a good strategy, you know, onshoring/ nearshoring either as a primary approach for developing and manufacturing drug products, as well as, the whole supply chain flowing into that drug product.

If not as a primary strategy, as a contingency, as a backup plan, you know, so that they can react to changes in the geopolitical environment, and it seems like they're changing every day. So I think in most of our sponsor companies that we work with and partners, I think it's a very wise strategy to start developing these contingency plans, if not just shifting completely to onshoring domestic development and manufacturing.

We have a number of clients who've begun shifting what they've done historically in China back to the US for those reasons. I think also, you know, what was driving a lot of that work towards the Eastern markets was, you know, speed and cost, right?

These other CDMOs abroad, they offer services for the price is very low. The speed is very high. But a number of our clients as a side effect of, you know, bringing stuff back to the US that they've done historically in China, are recognizing the inefficiencies even though it's on face faster and cheaper.

The issues that you deal with in terms of miscommunications, reiterating work, you know, data inconsistencies, manufacturing issues, the amount of work that needs to be reiterated or redone or the doubt that's created when the data or the documentation isn't complete be taken into account.

And so, these clients that have brought these activities back to the US that were traditionally done in China are starting to recognize the value in onshoring, just from a perspective of it may be more costly and slightly more time consuming on the front end, but you save on the back when you're avoiding these issues that I've just described.

So, what's been driven by the geopolitical environment and tariffs and uncertainty, creating this trend of onshoring, what started with that has, I think, evolved into becoming reacquainted with the value that's earned by working with high-quality domestic CDMOs, like us. It's been a pleasant side effect where a cost and time are at least on the front aren't quite as valued now as the quality of deliverable and the ultimate time saving in doing right the first time. That's been our perspective on the hot topic of conversation.

Dave Miller, PhD, explains how a development-first approach, scientific depth, and regulatory trust build lasting partnerships in the CDMO space.

The Importance for CDMOs of Partnering With a Sponsor’s Mindset



In part 2 of our 5-part interview series on the current CDMO landscape, Dave Miller, PhD, chief scientific officer at AustinPx, discusses how his organization’s evolution from a drug sponsor to a contract development and manufacturing organization (CDMO) shapes its approach to client partnerships. Initially founded to develop novel medicines, the company went on to reforumulate drug products to address unmet therapeutic needs. Once those assets were ready, they were partnered out, leaving behind a fully integrated infrastructure encompassing drug product development, CMC, clinical operations, and regulatory capabilities. This shift allowed the team to apply its expertise not just to its own assets, but across the industry.

Miller describes this as a “by developers for developers” mindset: “We were developers, we’re working with developers, so we are walking in step with them as we move forward.” This perspective means viewing each client’s molecule through the lens of a sponsor—tailoring development strategies as if the product were their own. That includes addressing complex formulation challenges, such as bioavailability issues in small molecules, and extending support beyond standard CDMO services into preclinical, clinical, and regulatory advice.

Miller sees differentiation in the CDMO market as requiring more than technical capabilities; companies must offer something unique and demonstrably useful, backed by a strong scientific and engineering foundation. Trust, he emphasizes, is a critical differentiator. A longstanding track record with regulatory agencies and intellectual property protection builds client confidence, particularly compared to some overseas markets where concerns about IP security persist. For Miller, the goal is long-term partnership, guiding a molecule from formulation through manufacturing tech transfer, while safeguarding client assets and enabling successful regulatory filings. This blend of technical depth, sponsor mindset, and trust-based collaboration, he argues, positions the company as an uncommon partner in a crowded CDMO landscape.

part 1 (Collaborative Innovation in CDMOs: Dave Miller, PhD, on Early Engagement, IP Strategy, and Advanced Formulation

), and be on the lookout for parts 3-5 to drop in the coming days!

*Editor’s Note: This transcript is a direct, unedited rendering of the original audio/video content. It may contain errors, informal language, or omissions as spoken in the original recording.



I think we're really unique and I've already touched on it a couple times in our previous questions in that we evolved from a sponsor ourselves. So we started with our novel KinetiSol platform. We had this unique tool that differentiated us from any other developers, and we utilized that tool to reformulate drug products to address specific unmet therapy needs.

So that was the evolution. Had a drug, we developed a tool and started utilizing that tool to create differentiated medicines and developed those for almost a decade ourselves. And then at the point that we had developed those assets to a place where they could be partnered, we partnered those assets off.

But what remained as the company was a fully integrated company that was really focused on drug product development as well as, you know, your standard sort of CMC, clinical operations, regulatory activities. So we had this infrastructure, and we realized that whereas before we were sort of leveraging one tool in KinetiSol to develop products, now we had all sorts of tools. And rather than just focus those on our own assets, we could open those to the entire industry, let the whole industry leverage our tools, our expertise towards advancing molecules. So that's kind of where our “by developers for developers” mindset comes from. Like we still feel, we still carry in our DNA that sponsor perspective. So when a client approaches us with their molecule and their problem statement and their target product profile, we view it through their lens. And so we want to develop that product as if it were our own asset. We were developers, we're working with developers, so we are walking in step with them as we move forward.

We've developed all sorts of novel products for our own pipeline. Like I said, with compounds like deferasirox and abiraterone and rivaroxaban and nintedanib, looking at the problem statements for those molecules and tailoring a development program and ultimately an end product to address the deficiencies of those drug products.

And so that framework is exactly how we interact with our clients. We understand their molecule, the challenges, the target product profile, the clinical development plan, and we implement the same sort of development strategies and approaches we took to our own pipeline. So, you know, even though we're an oral development, oral drug product development CDMO, and those are the tangible services we provide, there's a whole host of intangible services where we'll advise a client, on, say, their preclinical strategy, their clinical strategy, regulatory strategy, sort of just as sort of bonus we say, look, we've been here before. We've done this in the way that you're proposing and here's the issues they're going to face, and here's what we would suggest.

So it's sort of these intangible, soft services that our clients get that you don't get anywhere else because we once were a sponsor, we were developers ourselves, and now we work in tandem with other sponsors and other developers, not only to provide innovative formulation solutions that are tailored to their molecule, but also to be a partner, sort of an advisor at the various stages, just based on our own history.

That sort of mentality of a CDMO is becoming more common. But I think we're really unique as you look at CDMOs in the US and around the world. Not too many CDMOs that are fee for service now have a history of developing their own products and are able to apply that history to their clients' assets.

So I think we stand out in that regard. And, like I said, we still very much carry in our DNA that sponsor mentality and we bring that to the table when we start working with clients. And they feel that sort of partnership approach, that intangible advisor, they sign up for pharmaceutical development services, but they get so much more.

And I think that's the feedback we get from our clients. It's a unique experience in working with, Austin Pharmaceuticals.

Again, I think what we are leveraging is scientific expertise. So high science, we have, coming out of our history, we're focused primarily on enabling formulations, bioavailability and for very challenging small molecules that had various issues that impacted bioavailability.

So we developed a deep expertise and a wide array of tools for addressing bioavailability and issues, and creating enabled formulations. We have world class in that regard, but also carry a ton of knowledge in terms of just conventional pharmaceuticals, developing conventional dosage forms, manufacturing efficiency, GMP manufacturing, release, regulatory strategy.

So, we've got the high science approach, but also with a well-rounded experience in general. I think the high science is key, offering novel platforms that differentiate your company against what's out there in the landscape. There’s a lot of noise in the CDMO space.

I think what companies need to be differentiated is offering something different, something useful, and something that has a depth of history like we do with our bioavailability platform, but as I said, it's also about, again, co-development, not putting a client's compound through sort of a decision tree type structured development, but developing a tailored approach and tailored solution specifically for that molecule and demonstrating the scientific expertise and depth, as well as the engineering expertise and depth to take that molecule through formulation development, onto manufacturing tech transfer, to ensure that you're going to be the development and manufacturing partner for your client from start to finish.

The foundation of all of that, what underlies all of that, is having a robust quality system, a history with regulatory agencies, a history with IP generation and maintenance and retention that creates a feeling of trust among your clients that I think still, in comparison to Eastern markets, there's still some uncertainty there with respect to trustworthiness in terms of regulatory and IP, and I think that's still some… there's a natural sort of trustworthiness for domestic CDMOs and particularly CDMOs like us who have such an extensive regulatory and IP history that we will be trustworthy, will protect their asset, not only in terms of the services we provide, but also retaining their IP, generating new IP. And we can be a partner for them in providing what's needed for regulatory filing and standing behind it.

Dave Miller, PhD, discusses how tailored solutions, trust, and lifecycle planning are redefining partnerships in bio/pharmaceutical development.

Collaborative Innovation in CDMOs: Dave Miller, PhD, on Early Engagement, IP Strategy, and Advanced Formulation



In part 1 of our 5-part interview series on the current CDMO landscape, Dave Miller, PhD, chief scientific officer at AustinPx, emphasizes that the role of contract development and manufacturing organizations (CDMOs) is evolving beyond traditional, transactional service models toward deeper, collaborative partnerships. Miller describes this shift as “true co-development,” where innovation and scientific engagement form the foundation of client relationships. Central to the company’s approach is the application of novel technologies, such as its KinetiSol platform, to solve complex formulation challenges through tailored, science-driven solutions.

Miller notes that differentiation in today’s CDMO landscape hinges on high-touch, high-science engagement, intellectual property (IP) protection, and regulatory expertise. Drawing from AustinPx’s history as a former sponsor company, the team leverages extensive experience with the FDA and international regulatory bodies to guide clients in both domestic and global markets. IP retention, including overlooked compositional IP for drug products, is a priority.

The company increasingly engages with partners earlier in the molecule’s lifecycle—often shortly after candidate nomination—to ensure formulation strategies align with clinical and regulatory objectives. This early involvement supports smoother transitions from preclinical to clinical phases and fosters product designs with a clear line of sight toward commercialization.

According to Miller, the future of the CDMO sector lies in “collaborative innovation” that spans the entire spectrum of development, from early-stage design to market readiness. By operating as an extension of the sponsor’s own development team, AustinPx aims to provide customized, end-to-end solutions that address both immediate formulation needs and the long-term protection and differentiation of the therapeutic asset.

Be on the lookout for parts 2-5 to drop in the coming days!

I think from our experience and what we are dealing with, it's much more about partnerships these days than sort of transactional services. True co-development. And at the heart of that is sort of the novel platforms. You know, we have our KinetiSol platform that really is a driving force behind, you know, how we're partnering and developing products with our clients, but also high science, high touch.

You know, we're dealing with very complex formulation problems, and we offer novel solutions and novel insights. So I think it really comes down to just offering differentiating technologies, really focusing on partnering at the scientific level as opposed to just providing commodity services aimed at, you know, providing deliverables on time.

Also, with respect to ex-US partnerships, our clients also still value what they consider IP retention and trustworthiness, not just with respect to intellectual property, but also in regulatory settings as well. We have a long history as a company; in our prior incarnation, we were a sponsor company ourselves, developing our own pipeline of products and clinical development. So we have a long history of dealing with the FDA and other regulatory agencies outside of the United States. So that's certainly helpful for sponsors that are considering their options both domestic and abroad, as to who to select.

And going forward, it's all about differentiation and trustworthiness. And I think that's where we're really succeeding and as offering tailored solutions as well. Not just taking a molecule and putting it into some rigid framework, decision tree-type project progression, but rather, treating each molecule and each problem as unique and developing customized solutions.

So I think that's how we're at AustinPx differentiating ourselves from, from partners abroad, as well as domestically. I think we've seen sort of a paradigm shift towards much earlier engagement in the development and path of a molecule, interacting with us on the front end, shortly after even candidate nomination, toxicology studies, designing formulations, not just for clinic, but also to successfully transfer a molecule from preclinical into clinical development. So really early engagement. Establishing a CDMO partner who's going to be there as a co-developer, you know, the whole way through the process. So having capabilities that span the full spectrum of product development has been key for us. Um, 'cause we feel like the future in the CDMO space is collaborative innovation, and starting from the beginning in planning the development with the partner with all phases in mind and with the full lifecycle of the product in mind. So again, thinking about formulation insights, you know, that are tailored towards the exact phase of development that the molecule’s in now, but also with line of sight to the next step, aligning that with clinical strategy and regulatory positioning.

Also, again, talking about IP, I think compositional IP for drug products has been overlooked. I think a lot of companies focus primarily on the IP around the molecule as being what ultimately protects the asset. But we've kind of developed our approach, again, stemming from our own history as a sponsor company where the drug product, the composition of matter around the drug product, that IP is what really was protecting the asset.

So, we build that into our programs as well, where we're designing delivery systems specific for that molecule, solving simultaneous problems by tailoring the composition. And then in doing so, those problems… and providing the most robust, and high-performing dosage form, we sort of naturally generate novel composition matter IP and we're looking at that from day one.

In collaboration partners, even though it's years out, we're thinking about the full lifecycle of the molecule and protection of the asset on commercialization. So, that's where I think CDMOs… again, going back to just not just offering transactional services and checking the basic boxes of providing deliverables on a given timeline. It's more of an extension of the sponsor's development team and true collaborative innovation co-development. I think that's the expectation now. That's what we're doing.

Pendulum used for readings and hypnotism swinging with motion blur | Image Credit: © fergregory - stock.adobe.com

Vinay Prasad is resuming his position as head of FDA’s Center for Biologics Evaluation and Research (CBER) just over a week after stepping down (1). “At the FDA's request, Dr. Vinay Prasad is resuming leadership of the Center for Biologics Evaluation and Research,” US Health and Human Services spokesperson Andrew Nixon confirmed in a statement to Reuters (2). Less than 2 weeks earlier, Nixon told Biopharma Dive that “Dr. Prasad did not want to be a distraction to the great work of the FDA in the Trump administration and has decided to return to California to be with his family” (3).

Prasad, an oncologist with prior roles at the University of California San Francisco, the National Cancer Institute, and the National Institutes of Health, was appointed to lead CBER in May by FDA Commissioner Marty Makary (3). His return comes after a short 

departure that began as abruptly on July 30

Gene Therapy Safety and Regulatory Pressures

Prasad’s tenure has unfolded against the backdrop of heightened scrutiny over FDA’s regulation of advanced therapies, particularly gene therapies (3). Criticism intensified following the agency’s handling of Sarepta Therapeutics’ gene therapy for Duchenne muscular dystrophy (DMD). The therapy was linked to the deaths of two teens with advanced DMD. After a third death in a separate experimental therapy from the same company, FDA on July 18 halted shipments of the approved product due to safety concerns (3).

Ten days later, on July 28, the FDA revised its stance, allowing shipments to resume for the primary patient population (3). For pharmaceutical technology professionals, the rapid policy shifts underscore the challenges regulators face in balancing innovation with patient safety, especially for high-risk biologics and gene therapies.

Prasad’s leadership has drawn attention both inside and outside the agency. On July 20, activist Laura Loomer criticized him publicly, calling him a “progressive leftist saboteur” in a blog post (2). His return also takes place amid broader leadership transitions across the FDA and other US health agencies under Health Secretary Robert F. Kennedy Jr (4-6).

For those in drug development and manufacturing, the reinstatement signals continuity at a time when the biologics sector is under intense scientific, regulatory, and political pressure. The events surrounding Sarepta’s therapy highlight FDA’s role in managing cutting-edge treatments that promise significant benefits but also carry serious risks, decisions that can directly influence development timelines, manufacturing scale-up, and market access strategies.


Prasad Returns to FDA, Resuming Head of CBER Role

Vinay Prasad Returns to Role as Top Vaccine Regulator at FDA Days After Leaving US Agency

FDA Shake-Up: Vinay Prasad Exits Amid Tumult in Biologics Oversight

Implications of RFK Jr.’s CDC Vaccine Committee Overhaul for the Pharmaceutical Industry

RFK Jr.'s Removal of Thimerosal from Flu Vaccines Spurs Opposing Reactions

Reaction and Fallout as HHS ‘Winds Down’ mRNA Vaccine Development, Canceling $500 Million in Projects

Articles

Vinay Prasad has resumed his role as head of the FDA's Center for Biologics Evaluation and Research (CBER) shortly after stepping down. His leadership tenure has been marked by increased scrutiny over the FDA's regulation of advanced therapies, particularly gene therapies, following safety concerns with Sarepta Therapeutics' gene therapy for Duchenne muscular dystrophy. Prasad's return occurs amid broader leadership changes within the FDA and other health agencies. This reinstatement signals continuity in the biologics sector, which faces significant scientific, regulatory, and political pressures.

FDA reinstates Vinay Prasad to lead CBER as gene therapy safety concerns spotlight regulatory challenges in biotech manufacturing.

Prasad Returns to Head FDA’s CBER

Bio/pharmaceutical manufacturers are increasingly strained by evolving trade policies and tariff regimes, explained Jason Waite, international trade lead at Alston & Bird, in our 

 show more than three-quarters of UK businesses have already lost profit due to tariffs, with 91% expressing concern over the impact of tariffs in the next 12 months and nearly one-third saying they are “extremely concerned.” Companies are being forced to reassess operations, supply chains, and pricing strategies. “Adding to the confusion, President Trump has also announced wider tariffs against specific countries,” wrote Mike Hollan in our sister publication 

For those operating in the bio/pharmaceutical sector, tariffs have disrupted not only finished product shipments but also the flow of active pharmaceutical ingredients and raw materials critical for production, explains Waite. Regulatory complexities and inconsistent enforcement further compound these challenges, complicating long-term planning for compliance, cost forecasting, and sourcing.

The heightened sensitivity to trade policy in the sector underscores a broader concern: that global pharmaceutical manufacturing now depends on more than regulatory approval and technical quality; it also hinges on geopolitical stability and predictability in trade relationships.

Help us get a better picture of how new tariffs and trade policy have impacted you and your organization. Check back in a couple weeks to see where you stand among your peers! All who complete the survey will be entered for a chance to win a $25 Amazon gift card. See full rules below.


1. NO PURCHASE NECESSARY. OPEN ONLY TO LEGAL RESIDENTS OF THE UNITED STATES OF AMERICA WHO ARE AT LEAST 18 YEARS OLD AT TIME OF ENTRY. Void where prohibited by law. This sweepstakes begins on August 4, 2025 at 12:01 a.m. ET and ends on August 14, 2025 at 11:59 p.m. ET (“Promotion Period”). Sponsor’s computer is the official time keeping device for this Sweepstakes. Enter the Sweepstakes during the Promotion Period by: (1) Following the link to the Impacts of Tariffs & Trade Policy survey; and (2) fully completing and submitting your responses. Online entries must be received no later than 11:59 p.m. ET on August 14, 2025. Alternatively, anyone may enter the Sweepstakes by printing the words “Tarriff Sweepstake,” along with his or her name, title, date of birth, street address, city, state, zip, and phone number on a 3.5" by 5" white index card. Mail the card to MultiMedia Pharma Sciences, LLC Attn: C. Cole, 2 Commerce Drive, Cranbury, New Jersey 08512. To be considered eligible, entries must be received no later than August 14, 2025 at 11:59 p.m. ET. No methods of entry other than the methods specifically described herein will be accepted. Sponsor is not responsible for lost, late, misdirected or incomplete entries or unsuccessful attempts to enter. Incomplete entries and/or entries not received by the deadlines will not be eligible. Limit (1) one entry per person, per mailing address, per outer-mailing envelope, and per email address.

2. Winner will be selected in a random drawing from among all eligible entries received on or about August 15, 2025. Drawing will be conducted by MultiMedia Pharma Sciences whose decisions are final. Drawing times are subject to change or cancellation with or without notice. Odds of winning will depend upon the total number of eligible entries received. For winner’s name, send a separate self-addressed, stamped envelope to 2 Commerce Drive, Cranbury, NJ 08512 by September 15, 2025.

3. The prize (“Prize”) consists of the following: (1) Amazon Gift Card with Approximate Retail Value (“ARV”) of $25.00. Amazon is a registered trademark of Amazon.com, Inc. All rights reserved. Amazon.com, Inc. is not a participant or sponsor of this promotion.

4. The limit is one winner for the Prize. Winner will be notified by phone, email, overnight delivery or first class mail, as Sponsor shall determine. If Winner does not respond to Prize Notification as directed within five (5) days of the attempted notification date or if a Prize or Prize notification is returned as unclaimed or undeliverable, such Winner will be disqualified, Prize will be forfeited and an alternate winner will be selected. Upon disqualification, the Prize will be forfeited and no compensation will be given.

Prize is not transferable. No cash or prize substitutions, except the sponsor reserves the right to substitute prizes of equal or greater value. Acceptance of Prize constitutes permission to use that winner's name, likeness, and photo, and hometown for promotional and publicity purposes in any media

now known or later developed, worldwide, at no additional compensation unless prohibited by law. All costs and expenses associated with Prize acceptance and use not specified herein as being provided such as reservation fees, taxes, insurance and other expenses incurred by accepting the Prize are the sole responsibility of the Winner. By participating and accepting a prize, winner releases and agrees to hold harmless, MultiMedia Pharma Sciences, LLC, its respective parent company, subsidiaries, affiliates, service agencies, sponsors and any independent contractors of any kind arising in whole or in part, directly or indirectly, from acceptance, possession, use, or misuse of the prize or the participation in this sweepstakes or any sweepstakes-related activity.

5. This sweepstakes is open only to legal residents of the United States of America who are at least 18 years old at the time of entry. Void wherever prohibited by law. All federal, state, and local laws and regulations apply. Persons in any of the following categories are not eligible to participate or win a prize: (a) persons who since January 1, 2023 were or are employees or agents of MultiMedia Pharma Sciences, LLC, its respective parent company, subsidiaries, affiliates, service agencies, sponsors and any independent contractors of any kind of the above organizations; (b) individuals engaged in the development, production, or distribution of materials or the implementation of the sweepstakes and (c) immediate family of, or persons living in the same household as any person in any of the preceding categories.

6. Information collected by Sponsor in connection with this Sweepstakes may be used by Sponsor and shared with third parties involved in administration of the Sweepstakes. Information collected from entrants is subject to Sponsor’s Privacy Policy available at https://www.mjhlifesciences.com/privacy-policy/ Sponsor is not responsible for any disclosure made by the other or any third party. By participating in the Sweepstakes and providing your information, Entrants hereby agree to Sponsor’s collection and usage of their personal information and acknowledge that they have read and accepted Sponsor’s Privacy Policies.

7. This promotion is in no way sponsored, endorsed or administered by, or associated with Facebook, Instagram, X.com, LinkedIn, or Amazon. You understand that you are providing your information to Sponsor and not to Facebook, Instagram, X.com, LinkedIn. Facebook and Instagram are registered trademarks of Meta, Inc. X.com is a registered trademark of X Corp. LinkedIn is a registered trademark of LinkedIn Corporation. Amazon is a registered trademark of Amazon.com, Inc.

8. Sponsor reserves the right, to disqualify any individual found, in its sole opinion, to be tampering with the operation of the Sweepstakes; to be acting in violation of these Official Rules; or to be acting in an unsportsmanlike manner or with the intent to disrupt the normal operation of the Sweepstakes. Any use of robotic, automatic, macro, programmed, third party or like methods to participate in the Sweepstakes will void any attempted participation affected by such methods and the disqualification of the individual utilizing the same. CAUTION AND WARNING: ANY ATTEMPT TO DELIBERATELY DAMAGE ANY WEB SITE OR UNDERMINE THE LEGITIMATE OPERATION OF THIS PROMOTION IS A VIOLATION OF CRIMINAL AND CIVIL LAWS. SHOULD SUCH AN ATTEMPT BE MADE, THE SPONSOR RESERVES THE RIGHT TO SEEK DAMAGES OR OTHER REMEDIES FROM ANY SUCH PERSON(S) RESPONSIBLE FOR THE ATTEMPT TO THE FULLEST EXTENT PERMITTED BY LAW. Sponsor reserves the right to cancel, suspend and/or modify the Promotion, or any part of it, if any fraud, technical failures or any other factor beyond Sponsor’s reasonable control impairs the integrity or proper functioning of the Sweepstakes, as determined by Sponsor in its sole discretion. In such event, Sponsor reserves the right to award the prizes at random from among the eligible entries received up to the time of the impairment. If due to a printing, production or other error, more prizes are claimed than are intended to be awarded, Prize will be awarded in a random drawing from among all verified and validated entries. In no event will more than one Prize be awarded. In the event of any conflict with any Sweepstakes details contained in these Official Rules and Sweepstakes details contained in other Sweepstakes-related materials, the details of the Sweepstakes as set forth in these Official Rules shall prevail. 9. By entering, each entrant agrees for entrant and for entrant’s heirs, executors, and administrators (a) to release and hold harmless MultiMedia Pharma Sciences, LLC, Amazon.com, Inc, Meta, Inc., X Corp., LinkedIn Corporation and their respective officers, directors, and employees (collectively, “Released

Parties”) from any liability, illness, injury, death, loss, litigation, or damage that may occur, directly or indirectly, whether caused by negligence or not, from such entrant’s participation in the Sweepstakes and/or his/her acceptance, possession, use, or misuse of any prize or any portion thereof; (b) that Released Parties have neither made nor are in any manner responsible or liable for any warranty, representation or guarantee, express or implied, in fact or in law, with respect to any prize, including, without limitation, to such prize’s quality or fitness for a particular purpose; and (c) to be bound by these Official Rules and to waive any right to claim any ambiguity or error therein or in the Sweepstakes itself, and to be bound by all decisions of the Sponsor, which are binding and final. Failure to comply with these conditions may result in disqualification from the Sweepstakes at Sponsor’s sole discretion. Sponsor reserves the right to cancel, suspend and/or modify the Sweepstakes, or any part of it, if any fraud, technical failures or any other factor beyond Sponsor’s reasonable control impairs the integrity or proper functioning of the Sweepstakes, as determined by Sponsor in its sole discretion. Sponsor makes no warranties, and hereby disclaims any and all warranties, express or implied, concerning any prize furnished in connection with the Sweepstakes. WITHOUT LIMITING THE GENERALITY OF THE FOREGOING, SUCH PRIZES ARE PROVIDED “AS IS” WITHOUT WARRANTY OF ANY KIND, EITHER EXPRESS OR IMPLIED, AND SPONSOR HEREBY DISCLAIMS ALL SUCH WARRANTIES, INCLUDING BUT NOT LIMITED TO, THE IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE AND/OR NON-INFRINGEMENT.

10. This Promotion is subject to all applicable federal, state, and local laws and regulations. Issues concerning the construction, validity, interpretation and enforceability of these Official Rules shall be governed by the laws of the State of New Jersey, without regard to any principles of conflict of laws. All disputes arising out of or connected with this Promotion will be resolved individually, and without resort to class action, exclusively by a state or federal court located in Middlesex County, New Jersey. Should there be a conflict between the laws of the State of New Jersey and any other laws, the conflict will be resolved in favor of the laws of the State of New Jersey. To the extent permitted by applicable law, all judgments or awards shall be limited to actual out-of-pocket damages (excluding attorneys’ fees) associated with participation in this Promotion and shall not include any indirect, punitive, incidental and/or consequential damages.

11. The Sponsor and Administrator of this Sweepstakes is MultiMedia Pharma Sciences, LLC, 2 Commerce Drive, New Jersey 08512.

Bio/pharmaceutical manufacturers face significant challenges due to evolving trade policies and tariffs, impacting profits and operational strategies. A substantial portion of UK businesses report profit losses and express concerns about future tariff impacts. Tariffs disrupt the supply chain, affecting both finished products and raw materials, while regulatory complexities add to the difficulties. The industry's reliance on geopolitical stability and predictable trade relationships is increasingly evident. Companies must navigate these complexities to ensure compliance and cost-effectiveness, highlighting the critical role of trade policy in global pharmaceutical manufacturing.

Help us get a better picture of how new tariffs and trade policy have impacted you and your organization.